We provide a solution to the problems that many people have with taking pill-form medications exactly as prescribed by their physicians. PharmAdva offers a product that delivers improved quality of life for patients along with peace of mind for their loved ones, caregivers, and prescribing physicians.
Chief Executive Officer
Jonathan Sacks co-founded PharmAdva together with Dr. Michel Berg, concurrent with licensing four University of Rochester Medical Center (URMC) patents upon which the current — and future planned PharmAdva products — are based. Jonathan has driven development of the MedaCube unit from patent through seven prototype cycles to production, while establishing the company’s operating infrastructure, financing, and distribution model. Sacks has led 7 startups since 1993. As CEO of Millennium Computer Corp (currently named Vanteon) he led the firm from 3 to 450 employees, $65M of annual revenue, and sale to an industry leading public company where he served as Division President. He has been active in M&A driving corporate expansion and shareholder returns, leading 11 transactions exceeding $140M since 1996. Jonathan is a key investor in PharmAdva.
Chief Technology Officer
Joel Reiser serves as PharmAdva’s CTO and has been the driving force behind integration of PharmAdva’s hardware and software product development. Prior to PharmAdva, Mr. Reiser founded Millennium Computer Corp and perfectly positioned his software firm with cross-platform C/C++ software development, tech writing, and extensive quality control, which fueled the firm’s growth through three Inc 500 awards. Joel and his team contributed to the development of Millennium client’s products including numerous HP, Kodak and Lexmark drivers, Corel Draw, WordPerfect and hundreds of additional leading applications in retail software, hardware, IT and healthcare venues. Millennium was acquired in 1997, after which Reiser became CTO of the firm (renamed) Vanteon Corp, which remains a strong embedded development force in upstate New York. Joel is a key investor in PharmAdva.
VP of Engineering
Chuck DuBois leads PharmAdva’s software and hardware engineering efforts, both in-house and outsourced. Chuck has extensive experience in creating and driving teams for products of all sizes across multiple platforms. Leveraging his Computer Science and Imaging Science background from Rochester Institute of Technology, Chuck spent nearly 10 years with Millennium Computer Corp. and Vanteon Corp. growing and leading teams developing renowned software products for many corporations including HP, Kodak, Corel, Heidelberg, and many others. Subsequently, his 12-year role at Fujifilm focused his efforts to driving multiple product development teams in the creation and growth of highly-connected photofinishing solutions for lab, kiosk, mobile, and web offerings. He and his teams garnered product recognition through several best in class software awards, business recognition with multiple profitable offerings, as well as technical recognition through multiple patents.
Dr. Michel J. Berg
Chief Medical Officer
Dr. Michel J. Berg is co-founder and CMO of PharmAdva. He joined the University of Rochester School of Medicine and Dentistry faculty in 1993 and is currently an Associate Professor of Neurology and the Medical Director of the Strong Epilepsy Center. He has a special interest in technology for healthcare, and invented the core PharmAdva technology which URMC patented. He is involved in projects on enhancing medication adherence with smart medication dispensers, establishing the equivalence of generic anti-epilepsy drugs (AED), automating MRI analysis, seizure prediction from EEG, and the genetics of abnormalities of brain development with a focus on cerebral cavernous malformations. He is the chair of the American Epilepsy Society Task Force on Continuity of Medication Supply which is currently focused on the issue of generic equivalence of anti-epilepsy drugs. Dr. Berg is on the Scientific Advisory Board of the Angioma Alliance. He is co-author of the text, 100 Maxims in Clinical Neuroradiology, and has authored and coauthored numerous scientific articles in the above fields. Michel is a key investor in PharmAdva.
Chief Financial Officer
Andrew Maskery joins the PharmAdva team with over 20 years of experience in accounting and finance. Andrew graduated from the University of Southampton in England and then obtained his ACA qualification. He worked for Firth Rixson, an aerospace manufacturing company, for over 16 years. As VP Finance he led their finance function for the US and China operations. Maskery was involved in three corporate M&A transactions during his time at Firth Rixson, ultimately resulting in the sale of the company to Alcoa for $3B in 2014.